Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Humanin

HN, S14G-Humanin

Quick Stats
Studies 491
Trials 100
Score 2
2010 pubmed

Acute humanin therapy attenuates myocardial ischemia and reperfusion injury in mice.

Muzumdar. Radhika H RH; Huffman. Derek M DM; Calvert. John W JW; Jha. Saurabh S; Weinberg. Yoni Y; Cui. Lingguang L; Nemkal. Anjana A; Atzmon. Gil G; Klein. Laura L; Gundewar. Susheel S; Ji. Sang Yong SY; Lavu. Madhav M; Predmore. Benjamin L BL; Lefer. David J DJ

Key Findings

  • HNG reduced infarct size in a dose‑dependent way, with best effect at 2 mg/kg
  • HNG improved left‑ventricular ejection fraction and kept heart size normal after injury
  • HNG increased AMPK and eNOS activation while lowering pro‑apoptotic proteins (Bax, Bcl‑2)

Practical Outcomes

  • These results are promising but still early‑stage; the peptide was tested only in mice and given by injection, so there’s no ready‑to‑use protocol for people. Biohackers might watch for future human trials, but for now the main takeaway is that humanin analogs could become a future treatment for heart attacks, not a current DIY supplement.

Summary

In mouse experiments, giving a stronger version of the natural peptide humanin (called HNG) before or right after a simulated heart attack cut the amount of heart tissue that died and helped the heart pump better afterward. The protection seems to come from turning on energy‑regulating pathways (AMPK and eNOS) and lowering cell‑death signals.

Abstract

Humanin (HN), an endogenous antiapoptotic peptide, has previously been shown to protect against Alzheimer's disease and a variety of cellular insults. We evaluated the effects of a potent analog of HN (HNG) in an in vivo murine model of myocardial ischemia and reperfusion. Male C57BL6/J mice (8 to 10 week old) were subjected to 45 minutes of left coronary artery occlusion followed by a 24-hour reperfusion. HNG or vehicle was administered IP 1 hour prior or at the time of reperfusion. The extent of myocardial infarction per area-at-risk was evaluated at 24 hours using Evans Blue dye and 2-3-5-triphenyl tetrazolium chloride staining. Left ventricular function was evaluated at 1 week after ischemia using high-resolution, 2D echocardiography (VisualSonics Vevo 770). Myocardial cell signaling pathways and apoptotic markers were assessed at various time points (0 to 24 hours) following reperfusion. Cardiomyocyte survival and apoptosis in response to HNG were assessed in vitro. HNG reduced infarct size relative to the area-at-risk in a dose-dependent fashion, with a maximal reduction at the dose of 2 mg/kg. HNG therapy enhanced left ventricular ejection fraction and preserved postischemic left ventricular dimensions (end-diastolic and end-systolic), resulting in improved cardiac function. Treatment with HNG significantly increased phosphorylation of AMPK and phosphorylation of endothelial nitric oxide synthase in the heart and attenuated Bcl-2-associated X protein and B-cell lymphoma-2 levels following myocardial ischemia and reperfusion. HNG improved cardiomyocyte survival and decreased apoptosis in response to daunorubicin in vitro. These data show that HNG provides cardioprotection in a mouse model of myocardial ischemia and reperfusion potentially through activation of AMPK-endothelial nitric oxide synthase-mediated signaling and regulation of apoptotic factors. HNG may represent a novel agent for the treatment of acute myocardial infarction.

Study Information

Provider

pubmed

Year

2010

Date

2010-07-22T00:00:00.000Z

DOI

10.1161/atvbaha.110.205997